Orthofix Medical Inc. reported on May 21, 2026, that a recent FDA reclassification of bone growth stimulators and new CMS billing rules will likely lead to a 10% decline in Medicare reimbursement and updated its 2026 sales forecast to $838-$848 million with adjusted EBITDA of $90-$93 million. This is a significant event due to its impact on the company's financial outlook.